CLOs on the Move

White Oak Manor-Shelby

www.whiteoakmanor.com

 
White Oak Manor-Shelby is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Secure Doc Imaging

Secure Doc Imaging is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Taris Biomedical

Taris Biomedical is a Lexington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Beth Israel Lahey Health

Beth Israel Lahey Health is a new, integrated system providing patients with better care wherever they are. Care informed by world-class research and education. We are doctors and nurses, technicians and social workers, innovators and educators, and so many others. All with a shared vision for what health care can and should be.

Regency Hospital Company

Regency Hospital Company, LLC is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Regency Hospital Company, LLC is based in Alpharetta, GA. You can find more information on Regency Hospital Company, LLC at www.regencyhospital.com

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.